TY - JOUR
T1 - 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity
T2 - a retrospective study
AU - Takase, Naoto
AU - Matsumoto, Koji
AU - Onoe, Takuma
AU - Kitao, Akihito
AU - Tanioka, Maki
AU - Kikukawa, Yoshitaka
AU - Yamaguchi, Satoshi
AU - Fujiwara, Kiyoshi
AU - Negoro, Shunichi
N1 - Publisher Copyright:
© 2014, Japan Society of Clinical Oncology.
PY - 2015/6/11
Y1 - 2015/6/11
N2 - Background: Platinum agents are essential for treating gynecological malignancies, particularly ovarian cancer. However, multiple carboplatin doses may cause hypersensitivity reactions (HSRs). Carboplatin desensitization prevents life-threatening HSRs and promotes the successful completion of planned chemotherapy. Methods: Since January 2010, carboplatin desensitization was performed at our institution. Solutions with 1/1000, 1/100, and 1/10 dilutions of carboplatin and an undiluted solution were prepared in 250 mL of 5 % glucose. Each solution was administered as a 1-h intravenous infusion (4-step 4-h protocol). This retrospective analysis was approved by the institutional review board. Results: From January 2010 to December 2013, 20 patients with gynecological malignancies (median age 62 years, range 43–74 years) received desensitization treatment. The International Federation of Gynecology and Obstetrics stages at presentation were I, II, III, and IV in 1, 1, 15, 13 patients, respectively. During first-line and second-line treatments, 3 and 17 patients, respectively, experienced carboplatin-induced HSRs. The median carboplatin cycle number was 11 (range 2–16). In the first desensitization cycle, 17 (85 %) patients completed treatment without adverse events, 2 experienced Grade 1 HSRs but completed treatment, and 1 experienced Grade 3 HSR and discontinued treatment. The first desensitization cycle completion rate was 95 %. Of 83 desensitization cycles administered, 79 (95.2 %) were completed. No treatment-related deaths occurred. Conclusions: Most patients completed the planned chemotherapy. Our protocol could be conducted safely with shorter duration and simpler procedures than previous protocols. Carboplatin desensitization seems beneficial for patients with a history of carboplatin-induced HSRs; however, the risk of HSR recurrence still remains. Desensitization should therefore be performed only by well-trained staff.
AB - Background: Platinum agents are essential for treating gynecological malignancies, particularly ovarian cancer. However, multiple carboplatin doses may cause hypersensitivity reactions (HSRs). Carboplatin desensitization prevents life-threatening HSRs and promotes the successful completion of planned chemotherapy. Methods: Since January 2010, carboplatin desensitization was performed at our institution. Solutions with 1/1000, 1/100, and 1/10 dilutions of carboplatin and an undiluted solution were prepared in 250 mL of 5 % glucose. Each solution was administered as a 1-h intravenous infusion (4-step 4-h protocol). This retrospective analysis was approved by the institutional review board. Results: From January 2010 to December 2013, 20 patients with gynecological malignancies (median age 62 years, range 43–74 years) received desensitization treatment. The International Federation of Gynecology and Obstetrics stages at presentation were I, II, III, and IV in 1, 1, 15, 13 patients, respectively. During first-line and second-line treatments, 3 and 17 patients, respectively, experienced carboplatin-induced HSRs. The median carboplatin cycle number was 11 (range 2–16). In the first desensitization cycle, 17 (85 %) patients completed treatment without adverse events, 2 experienced Grade 1 HSRs but completed treatment, and 1 experienced Grade 3 HSR and discontinued treatment. The first desensitization cycle completion rate was 95 %. Of 83 desensitization cycles administered, 79 (95.2 %) were completed. No treatment-related deaths occurred. Conclusions: Most patients completed the planned chemotherapy. Our protocol could be conducted safely with shorter duration and simpler procedures than previous protocols. Carboplatin desensitization seems beneficial for patients with a history of carboplatin-induced HSRs; however, the risk of HSR recurrence still remains. Desensitization should therefore be performed only by well-trained staff.
KW - Carboplatin
KW - Desensitization
KW - Gynecological malignancy
KW - Hypersensitivity reaction
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=84930571668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930571668&partnerID=8YFLogxK
U2 - 10.1007/s10147-014-0731-1
DO - 10.1007/s10147-014-0731-1
M3 - Article
C2 - 25030546
AN - SCOPUS:84930571668
SN - 1341-9625
VL - 20
SP - 566
EP - 573
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -